StromaCare develops therapeutic biotechnology focused on cancer immunotherapy through stroma modulation, targeting stromal components that promote tumor growth and immune evasion. The company aims to enhance the delivery of therapeutic agents and facilitate tumor resection by advancing its lead product to First-in-Human clinical trials across multiple solid cancer types.
Funding
Funding not disclosed
Founders
Product
Problem
Solid tumors create a microenvironment, or stroma, that promotes tumor growth, prevents immune cell infiltration, and hinders effective drug delivery. Current cancer therapies often fail to address these stromal components, leading to limited efficacy and disease progression.
Solution
StromaCare is developing cancer immunotherapies that modulate the tumor stroma to improve treatment outcomes. By targeting specific stromal components that promote tumor growth and immune evasion, StromaCare aims to enhance the delivery of therapeutic agents to the tumor core and facilitate tumor resection. Their approach seeks to remodel the stroma, allowing for improved immune cell access and a more effective anti-tumor response. The company is advancing its lead product towards clinical trials, targeting multiple solid cancer types.
Target Audience
The primary target audience includes patients with solid tumors, oncologists, and researchers in the field of immuno-oncology seeking novel therapeutic strategies.
Features
- Identification and targeting of key tumoral stroma components involved in tumor growth and immune escape.
- Modulation of the stroma structure to enhance therapeutic agent delivery.
- Development of immunotherapies designed to improve immune cell infiltration into tumors.
- Preclinical research demonstrating the impact of stroma modulation on tumor microenvironment.